Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline Mutations

Overview

Journal JCO Precis Oncol

Specialty Oncology

Date 2020 Sep 14

PMID 32923864

Citations 11

Authors

Belinda Kingston

Caroline Bailleux

Suzette Delaloge

Gaia Schiavon

Veronique Scott

Magali Lacroix-Triki

T Hedley Carr

Iwanka Kozarewa

Heidrun Gevensleben

Zoe Kemp

Alex Pearson

Nicholas Turner

Fabrice Andre

Affiliations

Soon will be listed here.

Citing Articles

AKT kinases as therapeutic targets.

Hassan D, Menges C, Testa J, Bellacosa A J Exp Clin Cancer Res. 2024; 43(1):313.

PMID: 39614261 PMC: 11606119. DOI: 10.1186/s13046-024-03207-4.

Moving toward precision medicine to predict drug sensitivity in patients with metastatic breast cancer.

Bottosso M, Mosele F, Michiels S, Cournede P, Dogan S, Labaki C ESMO Open. 2024; 9(3):102247.

PMID: 38401248 PMC: 10982863. DOI: 10.1016/j.esmoop.2024.102247.

A New Frameshift Mutation of Gene Associated with Cowden Syndrome-Case Report and Brief Review of the Literature.

Jurca C, Fratila O, Ilias T, Jurca A, Catana A, Moisa C Genes (Basel). 2023; 14(10).

PMID: 37895258 PMC: 10606311. DOI: 10.3390/genes14101909.

AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.

Dunn S, Eberlein C, Yu J, Gris-Oliver A, Ong S, Yelland U Oncogene. 2022; 41(46):5046-5060.

PMID: 36241868 PMC: 9652152. DOI: 10.1038/s41388-022-02482-9.

A germline SNP in BRMS1 predisposes patients with lung adenocarcinoma to metastasis and can be ameliorated by targeting c-fos.

Liu Y, Chudgar N, Mastrogiacomo B, He D, Lankadasari M, Bapat S Sci Transl Med. 2022; 14(665):eabo1050.

PMID: 36197962 PMC: 9926934. DOI: 10.1126/scitranslmed.abo1050.

References

Eng C . Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet. 2000; 37(11):828-30. PMC: 1734465. DOI: 10.1136/jmg.37.11.828. View

Jones N, Bonnet F, Sfar S, Lafitte M, Lafon D, Sierankowski G . Comprehensive analysis of PTEN status in breast carcinomas. Int J Cancer. 2013; 133(2):323-34. DOI: 10.1002/ijc.28021. View

Komiya T, Blumenthal G, DeChowdhury R, Fioravanti S, Ballas M, Morris J . A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in . Oncologist. 2019; 24(12):1510-e1265. PMC: 6975943. DOI: 10.1634/theoncologist.2019-0514. View

Squarize C, Castilho R, Gutkind J . Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin. Cancer Res. 2008; 68(17):7066-72. DOI: 10.1158/0008-5472.CAN-08-0922. View

Knudson A . Two genetic hits (more or less) to cancer. Nat Rev Cancer. 2002; 1(2):157-62. DOI: 10.1038/35101031. View

Hyman D, Smyth L, Donoghue M, Westin S, Bedard P, Dean E . AKT Inhibition in Solid Tumors With AKT1 Mutations. J Clin Oncol. 2017; 35(20):2251-2259. PMC: 5501365. DOI: 10.1200/JCO.2017.73.0143. View

Patnaik A, Appleman L, Tolcher A, Papadopoulos K, Beeram M, Rasco D . First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas. Ann Oncol. 2016; 27(10):1928-40. PMC: 5035790. DOI: 10.1093/annonc/mdw282. View

Davies B, Guan N, Logie A, Crafter C, Hanson L, Jacobs V . Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015; 14(11):2441-51. DOI: 10.1158/1535-7163.MCT-15-0230. View

Song M, Salmena L, Pandolfi P . The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012; 13(5):283-96. DOI: 10.1038/nrm3330. View

10.

Iacobas I, Burrows P, Adams D, Sutton V, Hollier L, Chintagumpala M . Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation. Pediatr Blood Cancer. 2011; 57(2):321-3. DOI: 10.1002/pbc.23098. View

11.

Tamura K, Hashimoto J, Tanabe Y, Kodaira M, Yonemori K, Seto T . Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016; 77(4):787-95. PMC: 4819940. DOI: 10.1007/s00280-016-2987-9. View

12.

Luo S, Chen J, Mo X . The association of PTEN hypermethylation and breast cancer: a meta-analysis. Onco Targets Ther. 2016; 9:5643-50. PMC: 5026181. DOI: 10.2147/OTT.S111684. View

13.

Banerji U, Dean E, Perez-Fidalgo J, Batist G, Bedard P, You B . A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in -Mutated Breast and Gynecologic Cancers. Clin Cancer Res. 2017; 24(9):2050-2059. DOI: 10.1158/1078-0432.CCR-17-2260. View

14.

Tan M, Mester J, Ngeow J, Rybicki L, Orloff M, Eng C . Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012; 18(2):400-7. PMC: 3261579. DOI: 10.1158/1078-0432.CCR-11-2283. View

15.

Zhang C, Xu B, Liu P . Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer. Tumour Biol. 2016; 37(11):14831-14839. DOI: 10.1007/s13277-016-5381-7. View

16.

Zhang H, Liang F, Jia Z, Song S, Jiang Z . mutation, methylation and expression in breast cancer patients. Oncol Lett. 2013; 6(1):161-168. PMC: 3742525. DOI: 10.3892/ol.2013.1331. View

17.

Alimonti A, Carracedo A, Clohessy J, Trotman L, Nardella C, Egia A . Subtle variations in Pten dose determine cancer susceptibility. Nat Genet. 2010; 42(5):454-8. PMC: 3118559. DOI: 10.1038/ng.556. View

18.

Altomare D, Testa J . Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005; 24(50):7455-64. DOI: 10.1038/sj.onc.1209085. View

19.

Schmid G, Kassner F, Uhlig H, Korner A, Kratzsch J, Handel N . Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies. Pediatr Res. 2013; 75(4):527-34. DOI: 10.1038/pr.2013.246. View

20.

Agarwal R, Liebe S, Turski M, Vidwans S, Janku F, Garrido-Laguna I . Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome. Discov Med. 2015; 19(103):109-16. View